title: [Clinical efficacy of levofloxacin (LVFX) single-dose therapy in female acute uncomplicated cystitis].
abstract: Treatment of infections by the use of antimicrobial agents should be made essentially in a dose close to the minimally required dose. Acute uncomplicated cystitis in female fits as the subject for a single-dose therapy since it is an infection reactive relatively easily to antimicrobial agents. Accordingly, an assessment has been made regarding the therapeutic results of the single-dose therapy in 76 female cases of acute uncomplicated cystitis by the use of LVFX 200 mg which is a new quinolone. The urinary concentration more than MIC90 to Escherichia coli is sustained for about 3 days by this single-dose therapy. As a result of judging the therapeutic results from the reactions of the three clinical findings of pain on micturition, pyuria and bacteriuria, excellent therapeutic results were obtained with effective rates being 100% (76/76) on the day 3, 93.9% (46/49) on the day 7 and 94.4% (34/36) on the day 14. The rate of cystitic symptoms which recurred posed no problem, being 12.5% (5/40) up to three months, as investigated by a questionnaire. As a result of performing close urological examinations such as cystoscopy on six cases with insufficient results or recurrence, we could detect mild underlying conditions which are considered to be intractable factors in the bladder in three cases. From the above results, the single-dose therapy of acute uncomplicated cystitis in the female by LVFX which is a new quinolone was considered to be an excellent therapeutic drug from its characteristics such as its therapeutic results being the same as the conventional therapy by daily administration, excellent drug compliance, low cost, hard selectiveness of resistant strains, less side effects and furthermore it gives the opportunity of detecting a latent and mild underlying condition.
authors.affiliation: Department of Urology, Sapporo Medical College.
authors.forename: T
authors.initials: T
authors.lastname: Hirose
authors.forename: Y
authors.initials: Y
authors.lastname: Kumamoto
authors.forename: M
authors.initials: M
authors.lastname: Nishimura
authors.forename: M
authors.initials: M
authors.lastname: Aoki
authors.forename: T
authors.initials: T
authors.lastname: Tsukamoto
authors.forename: M
authors.initials: M
authors.lastname: Miyake
authors.forename: M
authors.initials: M
authors.lastname: Yanase
authors.forename: N
authors.initials: N
authors.lastname: Miyao
authors.forename: K
authors.initials: K
authors.lastname: Akagashi
authors.forename: A
authors.initials: A
authors.lastname: Yokoo
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D003556:Cystitis / Q000188:drug therapy* / Q000382:microbiology; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006801:Humans; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use* / Q000652:urine
chemical_list: D064704:Levofloxacin; D015242:Ofloxacin